Elicio Therapeutics, Inc. (ELTX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 9M 18M 27M Q1 '20: 865K Q2 '20: 729K Q3 '20: 827K Q4 '20: 459K Q1 '21: 371K Q2 '21: 540K Q3 '21: 1.5M Q4 '21: 25.9M Q1 '22: 1.6M Q2 '22: 653K Q3 '22: 0 Q4 '22: 0 Q1 '23: 0 Q1 '20 Q3 '20 Q1 '21 Q3 '21 Q1 '22 Q3 '22 Q1 '23

Gross Profit Quarterly

0 9M 18M 27M Q1 '20: 482K Q2 '20: 396K Q3 '20: 479K Q4 '20: 333K Q1 '21: 371K Q2 '21: 540K Q3 '21: 1.5M Q4 '21: 25.5M Q1 '20 Q2 '20 Q3 '20 Q4 '20 Q1 '21 Q2 '21 Q3 '21 Q4 '21

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-21M -14M -7M 0 7M 14M 21M Q1 '20: -12.6M Q2 '20: -17.3M Q3 '20: -11.6M Q4 '20: -13.8M Q1 '21: -19.9M Q2 '21: -18.2M Q3 '21: -15.8M Q4 '21: 14.6M Q1 '22: -14.5M Q2 '22: -6.2M Q3 '22: -5.8M Q4 '22: -6M Q1 '23: -7.8M Q2 '23: -7.8M Q3 '23: -10.8M Q4 '23: -9.4M Q1 '24: -10.2M Q2 '24: -10.9M Q3 '24: -10.3M Q4 '24: -13.5M Q1 '25: -10.7M Q2 '25: -10.1M Q3 '25: -8M Q4 '25: -8.8M Q1 '26: -10.6M Q2 '26: -10.4M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q1 '20: -13.2M Q2 '20: -20.3M Q3 '20: -17.7M Q4 '20: -28.9M Q1 '21: -36.7M Q2 '21: -17.1M Q3 '21: -15.7M Q4 '21: 14.9M Q1 '22: -7.1M Q2 '22: -7.3M Q3 '22: -7.2M Q4 '22: -6.7M Q1 '23: -8M Q2 '23: -7.6M Q3 '23: -10.7M Q4 '23: -8.9M Q1 '24: -11.8M Q2 '24: -7.2M Q3 '24: -18.8M Q4 '24: -14M Q1 '25: -11.2M Q2 '25: -10.6M Q3 '25: -10.1M Q4 '25: -7.7M Q1 '26: -11.8M Q2 '26: -8.2M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue Quarterly

0 150K 300K 450K Q1 '20: 383K Q2 '20: 333K Q3 '20: 348K Q4 '20: 126K Q1 '21: 0 Q2 '21: 0 Q3 '21: 0 Q4 '21: 433K Q1 '20 Q2 '20 Q3 '20 Q4 '20 Q1 '21 Q2 '21 Q3 '21 Q4 '21

Operating Cash Flow Quarterly

-24M -16M -8M 0 8M 16M 24M Q1 '20: -8.7M Q2 '20: -12.8M Q3 '20: -21.9M Q4 '20: 20.6M Q1 '21: -12.6M Q2 '21: -10.5M Q3 '21: -15.2M Q4 '21: -14.4M Q1 '22: -15.7M Q2 '22: 6.1M Q3 '22: -5.4M Q4 '22: -7.3M Q1 '23: -8.1M Q2 '23: -9.5M Q3 '23: -5.2M Q4 '23: -9.9M Q1 '24: -12.1M Q2 '24: -8.9M Q3 '24: -7.3M Q4 '24: -8.7M Q1 '25: -10.1M Q2 '25: -8.9M Q3 '25: -11.1M Q4 '25: -6.8M Q1 '26: -11.6M Q2 '26: -8.2M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Free Cash Flow Quarterly

-24M -16M -8M 0 8M 16M 24M Q1 '20: -8.8M Q2 '20: -12.8M Q3 '20: -21.9M Q4 '20: 20.6M Q1 '21: -12.6M Q2 '21: -10.8M Q3 '21: -15.3M Q4 '21: -14.4M Q1 '22: -15.7M Q2 '22: 5.6M Q3 '22: -5.4M Q4 '22: -7.4M Q1 '23: -8.2M Q2 '23: -9.5M Q3 '23: -5.2M Q4 '23: -9.9M Q1 '24: -12.1M Q2 '24: -9M Q3 '24: -7.3M Q4 '24: -8.8M Q3 '25: -11.1M Q4 '25: -6.8M Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q1 '20: 14.5M Q2 '20: 14.5M Q3 '20: 14.8M Q1 '21: 23.4M Q2 '21: 29.7M Q3 '21: 29.8M Q1 '22: 30M Q2 '22: 314.6K Q3 '22: 317.5K Q1 '23: 324.1K Q2 '23: 2.9M Q3 '23: 8.4M Q1 '24: 10.3M Q2 '24: 11.3M Q3 '24: 13.6M Q1 '25: 13M Q2 '25: 16.1M Q3 '25: 16.7M Q1 '26: 18.2M Q2 '26: 19.2M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-105.00 -70.00 -35.00 0.00 35.00 70.00 105.00 Q4 '20: -5.42 Q1 '21: -6.07 Q2 '21: -5.25 Q3 '21: -4.59 Q4 '21: -1.93 Q1 '22: -0.85 Q2 '22: -23.47 Q3 '22: -45.61 Q4 '22: -67.10 Q1 '23: -91.39 Q2 '23: -70.80 Q3 '23: -49.40 Q4 '24: -4.20 Q1 '25: -3.92 Q2 '25: -3.94 Q3 '25: -3.15 Q4 '25: -2.62 Q1 '26: -2.40 Q2 '26: -2.17 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.